We are live on ! Find out more
TVTX icon

Travere Therapeutics
TVTX

130 hedge funds and large institutions have $516M invested in Travere Therapeutics in 2019 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 54 increasing their positions, 32 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 32

47% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 17

7% more funds holding

Funds holding: 122 → 130 (+8)

1.41% less ownership

Funds ownership: 105.01% → 103.6% (-1.4%)

29% less call options, than puts

Call options by funds: $6.19M | Put options by funds: $8.72M

41% less capital invested

Capital invested by funds: $874M → $516M (-$358M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
130
Holders Change
+8
Holders Change %
+6.56%
% of All Funds
2.85%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
25
Increased
54
Reduced
32
Closed
17
Calls
$6.19M
Puts
$8.72M
Net Calls
-$2.54M
Net Calls Change
+$36.9M

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$65.9M
2
GPP
Great Point Partners
Connecticut
+$12.2M
3
State Street
State Street
Massachusetts
+$8.84M
4
Renaissance Technologies
Renaissance Technologies
New York
+$6.85M
5
Prudential Financial
Prudential Financial
New Jersey
+$4.2M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$24.8M
2
Invesco
Invesco
Georgia
-$17.6M
3
Handelsbanken Fonder
Handelsbanken Fonder
Sweden
-$12.3M
4
SCM
Scopia Capital Management
New York
-$11M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$4.64M +$2.75M +166,600 +71%
Charles Schwab
27
Charles Schwab
California
$3.91M +$309K +18,671 +6%
Two Sigma Investments
28
Two Sigma Investments
New York
$3.89M +$1.32M +79,757 +31%
SFM
29
Sphera Funds Management
Israel
$3.83M -$3.31M -200,475 -38%
AI
30
Atom Investors
Texas
$2.57M +$905K +54,758 +33%
ORI
31
Oak Ridge Investments
Illinois
$2.51M -$479K -28,987 -12%
GKIM
32
GW&K Investment Management
Massachusetts
$2.37M +$998K +60,363 +42%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$2.09M +$37.5K +2,272 +1%
DS
34
DRW Securities
Illinois
$2.09M +$2.98M +180,082 New
LOAMU
35
Lombard Odier Asset Management (USA)
New York
$2.03M -$413K -25,000 -13%
Axa
36
Axa
France
$1.92M +$2.73M +165,400 New
UBS Group
37
UBS Group
Switzerland
$1.89M +$2.32M +140,411 +617%
Bank of Montreal
38
Bank of Montreal
Ontario, Canada
$1.71M -$207K -12,512 -8%
Citadel Advisors
39
Citadel Advisors
Florida
$1.68M -$3.37M -204,167 -59%
Rafferty Asset Management
40
Rafferty Asset Management
New York
$1.51M +$1.05M +63,622 +96%
Citigroup
41
Citigroup
New York
$1.48M +$382K +23,117 +22%
State of New Jersey Common Pension Fund D
42
State of New Jersey Common Pension Fund D
New Jersey
$1.24M +$1.76M +106,700 New
Adage Capital Partners
43
Adage Capital Partners
Massachusetts
$1.16M +$1.65M +100,000 New
Tudor Investment Corp
44
Tudor Investment Corp
Connecticut
$1.14M +$618K +37,369 +61%
SIM
45
Spark Investment Management
New York
$1.07M -$881K -53,300 -36%
ARTA
46
A.R.T. Advisors
New York
$964K +$914K +55,300 +198%
Walleye Capital
47
Walleye Capital
New York
$900K +$1.28M +77,677 New
EU
48
Emory University
Georgia
$895K -$767K -46,420 -38%
MSL
49
Mackay Shields LLC
New York
$883K +$4.96K +300 +0.4%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$856K +$19.1K +1,157 +2%
1
2
3 4 5

TVTX Hedge Fund Activity: Q3 2019 in Review

130 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2019, worth a combined $516M — down 41% from $874M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new TVTX positions and 17 closed out — a net gain of 8 holders — while 54 added to existing stakes and 32 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $65.9M. The largest seller was Consonance Capital Management, cutting an estimated $24.8M.

  • 130 institutional investors held Travere Therapeutics (TVTX) as of Q3 2019, up from 122 in Q2 2019.
  • Funds reported $516M of Travere Therapeutics stock for Q3 2019, down 41% quarter-over-quarter.
  • 25 funds opened new Travere Therapeutics positions in Q3 2019 and 17 closed out, a net change of +8 holders.
  • The largest Travere Therapeutics buyer in Q3 2019 was RA Capital Management, an estimated $65.9M added.
  • The largest Travere Therapeutics seller in Q3 2019 was Consonance Capital Management, an estimated $24.8M sold.

Based on aggregated 13F filings for Q3 2019.